
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc. has demonstrated strong financial performance, highlighted by a record increase in Signatera MRD volumes, with a quarterly rise of 21,500 tests, translating to a remarkable 54% year-over-year growth. The company is positioned for further revenue growth, particularly through the expansion of reimbursement coverage in oncology, which is expected to enhance average selling prices and improve gross margins. Additionally, Natera's recent quarterly results showed an approximate revenue beat of $80 million, coupled with a substantial increase of $160 million in its revenue guidance for 2025, indicating a robust upward trajectory for the company's financial outlook.
Bears say
Natera Inc. is facing potential margin erosion due to anticipated reductions in in-network pricing as more commercial payors begin to offer coverage and as its target market expands to include average risk patients. The company is also vulnerable to negative impacts from regulatory setbacks, reimbursement issues, or delays in product launches, which could adversely affect its financial performance and stock movement. Additionally, the firm may encounter challenges in expanding into international markets, particularly if compelling data and effective reimbursement strategies are not established.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares